Navigation Links
VA National Campaign Takes Aim at Resistant Staph Infections
Date:10/18/2007

VA Medical Facilities Leaders in Fight Against MRSA

WASHINGTON, Oct. 18 /PRNewswire-USNewswire/ -- Building on the success of a pilot program that reduced a worrisome staph infection by 50 percent, the Department of Veterans Affairs (VA) has tough new screening requirements now in place in all of its 153 hospitals.

In addition to emphasizing its commitment to hospital hygiene and flagging affected patients for special precautions, VA facilities monitor all incoming patients on key units with nasal swabs and cultures for methicillin-resistant staphylococcus aureus (MRSA).

"VA demonstrated that dramatic reductions in MRSA-related infections are possible," said Acting Secretary of Veterans Affairs Gordon H. Mansfield. "VA's completion of our national deployment of these serious prevention measures reinforces VA's stature as one of the safest health care environments nationally."

Recently published data from the Centers for Disease Control and Prevention in collaboration with other researchers estimated there may be more than 94,000 MRSA cases a year in the United States associated with 18,650 deaths annually.

"MRSA is a dangerous infection, difficult to eradicate, that can cause pneumonia, wound or bloodstream infections," said Dr. Michael J. Kussman, VA's Under Secretary for Health. "Our ability to reduce the number of cases of MRSA infection enhances our ability to provide quality health care for veterans."

MRSA reflects the broader problem of multi-drug resistant organisms, which are difficult to treat with conventional antibiotics. In addition to hand-washing, isolation of infected patients and the use of gowns to prevent spread, the VA initiative focuses on "culture change" among its health care workers to improve awareness of the threat and to make infection prevention a routine component of care during each patient encounter every day.

After a successful pilot program in VA's Pittsburgh Health Care system,
'/>"/>

SOURCE Department of Veterans Affairs
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
7. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
8. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... Smith & Nephew ( SNN...ounce the signing of a technology development cont...that may lead to the creation of a fracture fixati...of the limbs of soldiers who sustain battlefield i...earch Projects Agency (DARPA), the central researc...
(Date:11/19/2009)... Warner Chilcott plc (Nasdaq: WCRX...nnounced secondary offering of 20,000,000 of its o...per share. The selling shareholders include funds...nt Banking, J.P. Morgan Partners (advised by CCMP ... other institutional investors and members of the ...
(Date:11/19/2009)...Newswire/ -- In response to an ever-increasing num...dicines, Operation Pangea II, involving 24 countri...th Organization,s International Medical Products A... the dangers of buying medicines online. ,, The...of arrests and the seizure of thousands of potenti...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 12469 1VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 12469 2VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 12469 3VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 12469 4Health Care Finance to Implement Districts First Medicaid Patient Data Hub Using MedPlus Technology 47898 1Health Care Finance to Implement Districts First Medicaid Patient Data Hub Using MedPlus Technology 47898 2Health Care Finance to Implement Districts First Medicaid Patient Data Hub Using MedPlus Technology 47898 3Health Care Finance to Implement Districts First Medicaid Patient Data Hub Using MedPlus Technology 47898 41st Class Kids Host Miniature Golf Tournament to Raise Money in Support of Continued Obesity Research 47893 1
...rseille, France and New Haven, CT, USA), a cancer ...for leukemia and breast cancer announced today,the...elopped on the MapQuant,Dx(TM) microarray diagnost...res a set of HER2-amplified genes that correlate w...ovides reliable, intelligible and decisive,informa...
...clinical,stage pharmaceutical company, announced t...ent Phase 2 trial of DCCR in dyslipidemic patients...gh triglycerides and mixed dyslipidemia,and includ...esenting with or,without hypertension. , The...ess the drug,s effect,on dyslipidemia and will eva...
Other Medicine Technology:Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer 2Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer 3Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia 2Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia 3
(Date:11/21/2009)...isions of Legislation, Continues Push for Progress...ov. 21 With the U.S. ...rdable Health Care for America Act (H.R. 3962), an...forward, Congress has taken decisive steps to fix ...RP hosted an educational forum to discuss the prov...
(Date:11/21/2009)...l apparel company launches men,s lab coats at Medi...Clemente, Calif. (PRWEB) November 21, 2009 -- Mede...today announced the launch of its men,s lab coats,...ternational trade fair for the medical industry he...s men,s collection with three varying lab coat sty...
(Date:11/21/2009)...Group merges their practice with that of E. Steven... (PRWEB) November 21, 2009 -- The New Hav...ibson, Dr. Dean Cloutier, Dr. John Plachtyna and D...practice with that of esteemed colleague Dr. E. St...ed to retire from dentistry in order to concentrat...
(Date:11/20/2009)...ire-FirstCall/ - NUCRYST Pharmaceuticals Corp. ann...s will be held on Monday, December 21, 2009. The p...wo special resolutions. The first special resoluti...substantially all of the assets of NUCRYST, substa...chase agreement dated November 10, 2009 among the ...
(Date:11/20/2009)...re/ -- Following a recall by Unilever The Stop &am...d,s Country Crock ® Side Dishes DELUXE Chedda...ide Dishes DELUXE Four Cheese Pasta due to an unde... dates and UPCs are affected: ,, Shedd,s Count...i Rice 21 oz, UPC 027400218316, Best By NOV 29 09 ...
Breaking Medicine News(10 mins):Health News:AARP Hosts Rep. Bill Foster In Health Care Reform Forum 2Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:New Haven Dental Group Expands Their Vision 2Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2
... facility on Sand Canyon Avenue , ...- Hoag Memorial Hospital Presbyterian has reached ...tate Investment Trust headquartered in Long Beach,...Tenet Healthcare Corporation (NYSE: THC) as Irvine...
... today announced a revised date to report its 2008.... ev3 will now report its 2008 second quarter,and ... 2008, after regular,market trading hours., The c...w its second quarter operating results and future,...
... Experience it at http://SutterHealth.org/an... an e-patient?,Studies show that 80 percent of Ame...ion. Thanks to Web 2.0, e-patients now have even m...alreport ,and you,ll see one of the ways Sutter He...
...ent-resistant, study shows , , THURSDAY, J...e evidence that a new AIDS drug brings significant...ents. , The drug, known as raltegravir (Isentress)...y 24 issue of the New England Journal of Medicine...
...lth and,safety services company, today announced t...les to Living Abroad.com and its multi-national em...-filled online guides to trusted,medical care in h...e assigned abroad on topics such as health service...
...Frank,Ervolino, ND, investigated a product that cl...isks associated with stimulants. He reports that,A...tural product from Zurich,Pharmaceuticals, makes n...DC estimates that greater than 30% of adults are o...
Other Medicine News:Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4Health News:Drug Holds Promise Against AIDS 2Health News:HTH Worldwide to Provide International Health Guide to Living Abroad.com 2Health News:New Natural Product from Zurich Pharmaceuticals Downs Appetite 2
Bledsoe Extender Knee Brace
Bledsoe Post-Op Knee Brace
Bledsoe Basic Knee Brace
Extensor™ Patellar Knee Support with Lateral Strap
Medicine Products: